TELA Bio (TELA) EBIT (2018 - 2026)

TELA Bio's EBIT history runs 9 years deep, the most recent figure standing at -$10.5 million for Q1 2026.

• In Q1 2026, EBIT fell 0.52% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at -$33.8 million (down 148.18% YoY), while the FY2025 annual figure was -$33.8 million, down 323.15% from the prior year.
• EBIT was -$10.5 million for Q1 2026 at TELA Bio, down from -$6.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $17.8 million in Q4 2024 to a low of -$12.3 million in Q4 2023.
• Historically, EBIT has averaged -$8.0 million across 5 years, with a median of -$9.8 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBIT surged 244.84% in 2024, then tumbled 137.38% in 2025.
• A 5-year view of EBIT shows it stood at -$9.4 million in 2022, then sank by 30.08% to -$12.3 million in 2023, then soared by 244.84% to $17.8 million in 2024, then sank by 137.38% to -$6.6 million in 2025, then plunged by 58.33% to -$10.5 million in 2026.
• The last three EBIT figures came in at -$10.5 million (Q1 2026), -$6.6 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.